Get the Stockscreener App
6.33
4.38%
-0.29
Meiragtx Holdings Plc stock is traded at $6.33, with a volume of 342.44K.
It is down -4.38% in the last 24 hours and up +26.85% over the past month.
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
See More
Previous Close:
$6.62
Open:
$6.57
24h Volume:
342.44K
Relative Volume:
0.57
Market Cap:
$551.31M
Revenue:
$14.02M
Net Income/Loss:
$-84.03M
P/E Ratio:
-4.3061
EPS:
-1.47
Net Cash Flow:
$-125.54M
1W Performance:
-7.73%
1M Performance:
+26.85%
6M Performance:
-1.09%
1Y Performance:
+44.19%
1-Day Range:
$6.33
$6.665
1-Week Range:
$6.31
$7.05
52-Week Range:
$3.85
$8.75
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings Plc
Sector
Industry
Phone
646-860-7985
Address
450 EAST 29TH STREET, NEW YORK, NY
Compare MGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
6.33 | 551.31M | 14.02M | -84.03M | -125.54M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Resumed | Chardan Capital Markets | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
Meiragtx Holdings Plc Stock (MGTX) Latest News
Bank of America Corp DE Has $389,000 Stock Position in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Millennium Management LLC - Defense World
(MGTX) Trading Signals - news.stocktradersdaily.com
Lucid Capital Initiates Buy Rating on MeiraGTx (MGTX) with $50 Target | MGTX Stock News - GuruFocus
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Jane Street Group LLC - Defense World
The Behavior Of MeiraGTx Holdings plc (MGTX) Stock Is Not As Predictable As You Think - Stocksregister
BNP Paribas Financial Markets Sells 3,322 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
Nuveen Asset Management LLC Boosts Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
ProShare Advisors LLC Purchases 4,910 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Buys 13,111 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
Some Confidence Is Lacking In MeiraGTx Holdings plc (NASDAQ:MGTX) As Shares Slide 25% - simplywall.st
(MGTX) Technical Data - news.stocktradersdaily.com
Northern Trust Corp Boosts Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by D. E. Shaw & Co. Inc. - Defense World
Prosight Management, LP Reduces Stake in MeiraGTx Holdings PLC - GuruFocus
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
FY2025 EPS Estimates for MeiraGTx Cut by Chardan Capital - Defense World
Price T Rowe Associates Inc. MD Grows Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
How to Take Advantage of moves in (MGTX) - news.stocktradersdaily.com
Tower Research Capital LLC TRC Buys 2,016 Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
Chardan Capital Lowers MeiraGTx (NASDAQ:MGTX) Price Target to $35.00 - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Sold by Voya Investment Management LLC - Defense World
Dimensional Fund Advisors LP Has $2.43 Million Stock Position in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Announces the Presentation of Four Posters at the Ameri - GuruFocus
Chardan Adjusts MeiraGTx Price Target to $35 From $38, Maintains Buy Rating - marketscreener.com
MGTX: Chardan Capital Lowers Price Target but Maintains Buy Rati - GuruFocus
MGTX: Chardan Capital Lowers Price Target but Maintains Buy Rating | MGTX Stock News - GuruFocus
MeiraGTx (MGTX) Reports Strong Q1 Revenue Growth and Advances Cl - GuruFocus
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - The Manila Times
MeiraGTx Holdings PLC Q1 2025 Earnings: EPS Misses at -$0.51, Re - GuruFocus
MeiraGTx Holdings to Present Four Poster Sessions at ASGCT 2025 Annual Meeting - Nasdaq
Dated alert on MeiraGTx collaboration with Hologen AI withdrawn - marketscreener.com
MeiraGTx Reports First Quarter 2025 Financial and Operational Results - ADVFN
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
MeiraGTx Holdings plc SEC 10-Q Report - TradingView
MeiraGTx Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Wells Fargo & Company MN Has $144,000 Stock Position in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMA - GuruFocus
MeiraGTx (MGTX) Gains RMAT Designation for Parkinson's Treatment - GuruFocus
FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment By Investing.com - Investing.com South Africa
MeiraGTx (MGTX) Gains FDA RMAT Designation for Parkinson's Treat - GuruFocus
MeiraGTx gets FDA RMAT status for its Parkinson’s disease treatment - Seeking Alpha
MeiraGTx (MGTX) Gains FDA RMAT Designation for Parkinson's Treatment | MGTX Stock News - GuruFocus
MeiraGTx Holdings Receives FDA RMAT Designation for AAV-GAD - TipRanks
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease - The Manila Times
FDA grants RMAT status to MeiraGTx’s Parkinson’s treatment - Investing.com
MeiraGTx Holdings Receives RMAT Designation from FDA for AAV-GAD Gene Therapy in Parkinson's Disease - Nasdaq
Invesco Ltd. Increases Stake in MeiraGTx Holdings plc (NASDAQ:MGTX) - Defense World
MeiraGTx Holdings PLC expected to post a loss of 49 cents a shareEarnings Preview - TradingView
MeiraGTx Holdings plc's (NASDAQ:MGTX) Shift From Loss To Profit - simplywall.st
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):